The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

11 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists.EBI
James Black Foundation
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.EBI
Bristol-Myers Squibb
Side chain cyclization based on serine residues: synthesis, structure, and activity of a novel cyclic analogue of the parathyroid hormone fragment 1-11.EBI
University Of Padova
Emerging targets in osteoporosis disease modification.EBI
Amgen
Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe.EBI
Pharmaceutical Research Institute
Discovery of novel PTHR1 antagonists: Design, synthesis, and structure activity relationships.EBI
Daiichi Sankyo
New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm.EBI
Astrazeneca
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.EBI
Bristol-Myers Squibb
Lead Optimization and Avoidance of Reactive Metabolite Leading to PCO371, a Potent, Selective, and Orally Available Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist.EBI
Chugai Pharmaceutical
Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism.EBI
Chugai Pharmaceutical
Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad? Residue Distribution.EBI
University Of Wisconsin-Madison